Quizartinib (AC220)

Name: Quizartinib (AC220)
Brand: Selleck Chemicals
SKU: S1526
Rating: 5 (77 reviews)

For research use only.

Catalog No.S1526

77 publications

CAS No. 950769-58-1

Quizartinib (AC220) is a second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM in MV4-11 and RS4;11 cells, respectively, 10-fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Quizartinib (AC220) induces apoptosis of tumor cells. Phase 3.

Selleck's Quizartinib (AC220) has been cited by 77 publications

Cancer Cell, 2018, 34(2):315-330

PubMed: 30033091 ( click the link to review the publication )

Nat Med, 2017, 23(1):69-78

PubMed: 27941792 ( click the link to review the publication )

Autophagy, 2021, 1-10

PubMed: 33446043 ( click the link to review the publication )

Cancer Discov, 2021, candisc.0738.2020

PubMed: 33436370 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Thorac Cancer, 2021, 10.1111/1759-7714.13849

PubMed: 33566442 ( click the link to review the publication )

Cell Rep, 2020, 33(1):108221

PubMed: 33027668 ( click the link to review the publication )

Haematologica, 2020, 15 pii: haematol 2019 244020

PubMed: 32414851 ( click the link to review the publication )

Mol Cell Proteomics, 2020, 10.1074/mcp.RA119.001504

PubMed: 32102969 ( click the link to review the publication )

Eur J Med Chem, 2020, 193:112232

PubMed: 32199135 ( click the link to review the publication )

J Cell Mol Med, 2020, 24(3):2308-2318

PubMed: 31881122 ( click the link to review the publication )

J Cell Mol Med, 2020, 25

PubMed: 32450611 ( click the link to review the publication )

Sci Rep, 2020, 10(1):16187

PubMed: 32999332 ( click the link to review the publication )

Sci Rep, 2020, 10(1):1906

PubMed: 32024878 ( click the link to review the publication )

Transl Oncol, 2020, 1;13(4):100766

PubMed: 32247263 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Pharmacol Res, 2020, 151:104556

PubMed: 31778791 ( click the link to review the publication )

FEBS Open Bio, 2020, 10.1002/2211-5463.12827

PubMed: 32128992 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Sci Transl Med, 2019,

PubMed: 31484791 ( click the link to review the publication )

Autophagy, 2019, 15(9):1558-1571

PubMed: 30821613 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31554189 ( click the link to review the publication )
Theriogenology, 2019, 126:145-152

PubMed: 30553232 ( click the link to review the publication )

Cell Rep, 2019, 26(11):2916-2928.e13

PubMed: 30865883 ( click the link to review the publication )

FEBS Lett, 2019, 593(16):2162-2176

PubMed: 31135968 ( click the link to review the publication )

Hemasphere, 2019, 3(2):e182

PubMed: 31723821 ( click the link to review the publication )

Oncotarget, 2019, 10(58):6111-6123

PubMed: 31692922 ( click the link to review the publication )

Blood, 2018, 25;131(4):426-438

PubMed: 29187377 ( click the link to review the publication )

Blood, 2018, 132(1):67-77.

PubMed: 29784639 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(7):1716-1726

PubMed: 29330206 ( click the link to review the publication )

Leukemia, 2018, 32(2):313-322

PubMed: 28895560 ( click the link to review the publication )

Haematologica, 2018, haematol.2018.189399

PubMed: 29748445 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(10):2417-2429

PubMed: 29463558 ( click the link to review the publication )

Oncogene, 2018, 37(6):787-797

PubMed: 29059168 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):138

PubMed: 29374185 ( click the link to review the publication )

Neoplasia, 2018, 20(1):1-11

PubMed: 29172076 ( click the link to review the publication )

Nephrol Dial Transplant, 2018, 10.1093/ndt/gfy385

PubMed: 30590794 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0196805

PubMed: 29723246 ( click the link to review the publication )

Exp Hematol, 2018, 58:52-58

PubMed: 28947392 ( click the link to review the publication )

J Ophthalmol, 2018, 2018:2518568

PubMed: 29854425 ( click the link to review the publication )

Oncotarget, 2018, 9(76):34240-34258

PubMed: 30344940 ( click the link to review the publication )

Leukemia, 2018, 32(11):2374-2387

PubMed: 29743719 ( click the link to review the publication )

Oncotarget, 2018, 9(24):16917-16931

PubMed: 29682194 ( click the link to review the publication )

Blood, 2017, 130(1):48-58

PubMed: 28490572 ( click the link to review the publication )

Leukemia, 2017, 31(11):2336-2346

PubMed: 28280274 ( click the link to review the publication )

Cancer Res, 2017, 77(7):1697-1708

PubMed: 28108507 ( click the link to review the publication )
Leuk Lymphoma, 2017, 10.1080/10428194.2017.1289522

PubMed: 28276286 ( click the link to review the publication )

Blood Adv, 2017, 1(20):1635-1644

PubMed: 29296810 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52026-52044

PubMed: 28881711 ( click the link to review the publication )

Blood, 2016, 127(23):2890-902

PubMed: 27099147 ( click the link to review the publication )

Cancer Res, 2016, 76(6):1528-37

PubMed: 26822154 ( click the link to review the publication )

Cancer Res, 2016, 76(5):1214-24

PubMed: 26833125 ( click the link to review the publication )

Sci Rep, 2016, 6:28032

PubMed: 27346558 ( click the link to review the publication )

Ann Hematol, 2016, 95(5):783-91

PubMed: 26891877 ( click the link to review the publication )

PLoS One, 2016, 11(7):e0158290

PubMed: 27387666 ( click the link to review the publication )

Int J Hematol, 2016, 103(1):95-106

PubMed: 26590920 ( click the link to review the publication )

Leukemia, 2015, 29(12):2382-9

PubMed: 26172401 ( click the link to review the publication )

Leukemia, 2015, 29(12):2390-2

PubMed: 26108694 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Oncotarget, 2015, 6(35):38061-78

PubMed: 26515730 ( click the link to review the publication )

Sci Adv, 2015, 1(8):e1500221

PubMed: 26601252 ( click the link to review the publication )

Blood, 2014, 123(18):2826-37

PubMed: 24668492 ( click the link to review the publication )

Blood, 2014, 123(5):734-42

PubMed: 24282218 ( click the link to review the publication )

Nat Commun, 2014, 5:3672

PubMed: 24739485 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2092-103

PubMed: 24436473 ( click the link to review the publication )

Leukemia, 2014, 28(11):2197-205

PubMed: 24699302 ( click the link to review the publication )

Leukemia, 2014, 28(2):293-301

PubMed: 23748345 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 10.1073/pnas.1320661111

PubMed: 24623852 ( click the link to review the publication )

Cancer Discov, 2014, 4(2):200-15

PubMed: 24362263 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2315-27

PubMed: 25053825 ( click the link to review the publication )
J Biol Chem, 2014, 289(45):31053-65

PubMed: 25237195 ( click the link to review the publication )

PLoS One, 2013, 8(8): e71266

PubMed: 23967177 ( click the link to review the publication )

PLoS One, 2013, 8(9):e74653

PubMed: 24040307 ( click the link to review the publication )

Leuk Res, 2013, 37(11):1557-64

PubMed: 23998902 ( click the link to review the publication )

Br J Pharmacol, 2012, 166(3):858-76

PubMed: 22250956 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Target Protein Ligand Inhibitors

Biological Activity

Description

Features

The most potent cellular FLT3-ITD inhibitor.

Targets

FLT3 (ITD) ^[1] (MV4-11 cells)	FLT3 (WT) ^[1] (RS4;11 cells)
1.1 nM	4.2 nM

In vitro

AC220, a unique, potent and selective inhibitor of FLT3, has high affinity for FLT3 with a K_d value of 1.6 nM. AC220 inhibits the autophosphorylation of FLT3 in the human leukemia cell lines MV4-11 which harbor a homozygous FLT3-ITD mutation and is FLT3 dependent, and RS4;11 which expresses wild-type FLT3 with IC50 values of 1.1 nM and 4.2 nM, respectively. AC220 is the most potent cellular FLT3-ITD inhibitor, leading to the most significant inhibition of MV4-11 cell proliferation with IC50 of 0.56 nM compared to all other FLT3 inhibitors whose IC50 values range from 0.87 nM to 64 nM. AC220 has no inhibitory activity against the proliferation of A375 cells which harbor an activating mutation in BRAF and are not FLT3 dependent, indicating a large window between FLT3 inhibition and general cytotoxic effects. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HL60/VCR	NG\0bpdHfW6ldHnvckBCe3OjeR?=	Mn;xNE4yNTFyIN88US=>	M{ThW\|MxKG2rbh?=	MXXlcohidmOnczD1dJRic2Vib3[gd5Vje3S{YYTld{Bw\iCDQlPHNkBidmRiQVLDRlEhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	M2PkWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[3NVc4Lz5{M{m2O\|E4PzxxYU6=
K562/ABCB1	M2rTUWZ2dmO2aX;uJGF{e2G7	M4rOS\|AvOS1zMDFOwG0>	NVnwW2lYOzBibXnu	MXvlcohidmOnczD1dJRic2Vib3[gd5Vje3S{YYTld{Bw\iCDQlPHNkBidmRiQVLDRlEhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	NH3LVXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
8226/MR20	NIHsbHVHfW6ldHnvckBCe3OjeR?=	MY[wMlEuOTBizszN	NHLvXlI{OCCvaX6=	MoPr[Y5p[W6lZYOgeZB1[WunIH;mJJN2[nO2cnH0[ZMhd2ZiQVLDS\|Ih[W6mIFHCR2IyKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz	NFTSOIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
K562/ABCG2	MmjxSpVv[3Srb36gRZN{[Xl?	M2rKcVAvOS1zMDFOwG0>	NX74WGNYOzBibXnu	MXvlcohidmOnczD1dJRic2Vib3[gd5Vje3S{YYTld{Bw\iCDQlPHNkBidmRiQVLDRlEhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4N{G3O{c,OjN7NkexO\|c9N2F-
MCF-7 FLV1000	MULLbY5ie2ViQYPzZZk>	M{HyT\|DjiJN\|MDFCuW0>	Mlq1OUBucW5?	MYLk[YNz\WG\|ZYOgX\|EzPUmfLVnBRXAheGixdH;sZYJmdGmwZzDv[kBCSkOEMTDheEBKSzVyIH;mJFMvOyEQvF2=	NIG3R5c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{m2O\|E4Pyd-MkO5OlcyPzd:L3G+
MCF-7 FLV1000	NHnYbIhMcW6jc3WgRZN{[Xl?	NIO5bZkx6oDVM{CgxtVO	MlHhOUBucW5?	NFyyRWxl\WO{ZXHz[ZMhYzF{NVndMWlCSVBicHjveI9t[WKnbHnu[{Bw\iCDQlPCNkBifCCLQ{WwJI9nKDBwMEeg{txO	MmPhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7NkexO\|coRjJ\|OU[3NVc4RC:jPh?=
K562/ABCG2	NFP6TXFE\WyuIG\pZYJqdGm2eTDBd5NigXN?	M3vJTFAvOS9yLkWvNUDDvU1?	NHHNblM6PiCq	NXHuNItGe2Wwc3n0bZpmeyCNNU[yM2FDS0d{IHPlcIx{KHSxIH3peI95[W62cn;u[UB1d3CxdHXjZY7DqA>?	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4N{G3O{c,OjN7NkexO\|c9N2F-
8226/MR20	Ml7zR4VtdCCYaXHibYxqfHliQYPzZZl{	M4LwV\|AvOSEEtV2=	NXPGVINvQTZiaB?=	M1y0dJNmdnOrdHn6[ZMhUzV4Mj;BRmNIOiClZXzsd{B1dyCvaYTvfIFvfHKxbnWgeI9xd3SnY3HuxsA>	M3vNdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OU[3NVc4Lz5{M{m2O\|E4PzxxYU6=
HMC1.1	MkX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXzJR\|UxRTF2IH7N	MoDyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
HMC1.2	MnXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGCyXHdKSzVyPUG3Nlchdk1?	Ml\TQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
p815	NUHJSHQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWfJR\|UxRTR2NTDuUS=>	NWP4SYRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
Kasumi-1	M1XsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MX\JR\|UxRTN4IH7N	MmLmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
M-07e + SCF	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Mo\PTWM2OD15NzDuUS=>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
EOL-1	NFrseIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXTJR\|UxRTFibl2=	NV[wcINvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
MV4;11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlXFTWM2ODxiMTDuUS=>	NV;3WG9HRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVc{OTdpPkKzOFk4OzF5PD;hQi=>
MOLM14	MnPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHG3ZZBKSzVyPDCxJI5O	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.221	M4nrXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFHoN29KSzVyPU[3OUBvVQ>?	MnXvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.279	NWPDU2dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn;kTWM2OD1\|NEO0JI5O	MnThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.299	MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYTJR\|UxRTd{NEigcm0>	NGPoSI49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.305	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1PYNGlEPTB;N{C3PUBvVQ>?	MnfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
Pat.375	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NGrsWXlKSzVyPUWwN{BvVQ>?	NFzEOVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.379	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmjGTWM2OD16ME[gcm0>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.368	MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mni4TWM2OD1{N{CwJI5O	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.601	M{LYemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4D1UWlEPTB;MUG1N{BvVQ>?	NFvHdYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
HMC1.1	M37sdWFxd3C2b4Ppd{BCe3OjeR?=			Mof0TWM2OD1\|MTDuUS=>	MlGxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
p815	NEnveVVCeG:ydH;zbZMhSXO\|YYm=			MmTGTWM2OD1\|NEGgcm0>	M2[2[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3N\|E4Lz5{M{S5O\|MyPzxxYU6=
Kasumi-1	NGPvSZZCeG:ydH;zbZMhSXO\|YYm=			NGnZN5JKSzVyPU[3JI5O	MoTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUezNVcoRjJ\|NEm3N\|E4RC:jPh?=
M-07e + SCF	NGrWXIxCeG:ydH;zbZMhSXO\|YYm=			MYrJR\|UxRTd6IH7N	NHTCXY89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
EOL-1	MnjpRZBweHSxc3nzJGF{e2G7			M2rGdGlEPTB:IEGgcm0>	NH\Qbos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
MV4;11	NH;sRW5CeG:ydH;zbZMhSXO\|YYm=			NYH6ZoM4UUN3ME2yJI5O	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
MOLM14	NHLHPVRCeG:ydH;zbZMhSXO\|YYm=			NV7vSIFxUUN3ME2zJI5O	NHH4T209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
GIST822	NI\sRmxCeG:ydH;zbZMhSXO\|YYm=			MlWzTWM2OD1zMEmgcm0>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzR7N{OxO{c,OjN2OUezNVc9N2F-
Pat.368	MYnBdI9xfG:\|aYOgRZN{[Xl?			MXXJR\|UxRTJ7OUigcm0>	NHP4cW09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
Pat.601	NFjRellCeG:ydH;zbZMhSXO\|YYm=			NYn4fpNkUUN3ME24O\|Yhdk1?	NFLxSmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{S5O\|MyPyd-MkO0PVc{OTd:L3G+
MV4-11	M2jr[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2TFe\|czKGh?	NFvRPG5KSzVyPUCuN{BvVQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
MOLM-14	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2fGNlczKGh?	MkPuTWM2OD1yLkGgcm0>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
SEM-K2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEfHXpY4OiCq	NYG4ZotoUUN3ME2wMlQhdk1?	M2rtN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
RS4;11	M3\Qcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIm2N4Q4OiCq	NE\oSmhKSzVyPkGwMFAxOCCwTR?=	M1;aOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
THP-1	M{\5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWXxR2pYPzJiaB?=	NFjERVVKSzVyPkGwMFAxOCCwTR?=	M4nIblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEGyPVMyLz5{M{SxNlk{OTxxYU6=
MV4-11	MV\BdI9xfG:\|aYOgRZN{[Xl?		NVLxZm9RQC9{NDDo	MVLpcoR2[2W\|IIPp[45q\mmlYX70JIFv\CCmb4PlMYRmeGWwZHXueEBRSVKSIHPs[YF3[WenIHHu[EBi[2O3bYXsZZRqd25ib3[gd5VjNTKQIFTORS=>	MnG2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
MOLM-14	Mn\aRZBweHSxc3nzJGF{e2G7		MkXMPE8zPCCq	MonWbY5lfWOnczDzbYdvcW[rY3HueEBidmRiZH;z[U1l\XCnbnTlcpQhWEGUUDDjcIVifmGpZTDhcoQh[WOldX31cIF1cW:wIH;mJJN2[i1{TjDEUmE>	Ml[5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2MUK5N\|EoRjJ\|NEGyPVMyRC:jPh?=
SEM-K2	NUPWcXZlSXCxcITvd4l{KEG\|c3H5		NULycI1yQC9{NDDo	NXXkSGplcW6mdXPld{B{cWewaX\pZ4FvfCCjbnSg[I9{\S2mZYDlcoRmdnRiUFHSVEBkdGWjdnHn[UBidmRiYXPjeY12dGG2aX;uJI9nKHO3Yj2yUkBFVkF?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzRzMkmzNUc,OjN2MUK5N\|E9N2F-
AML	M2LoT2N6fG:2b4jpZ4l1gSCjc4PhfS=>			NGfoTIFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCVUxiY3XscJMhcXOxbHH0[YQh\nKxbTDy[YxieHOnZDDhZ5V1\SCveXXsc4llKGyndXvlcYliKHCjdHnlcpQhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHH0bY9vKGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFAxOyEQvF2u	NV;wdnpIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
MV4-11	M4\y[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		NHHSRXU4OiCqcoO=	NGfPd5JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOXjRvMUGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOnbHygeIl1\XJvYnz1[UBie3OjeTygTWM2OCB;IECuNFAxPTZizszNMi=>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
blast cells	MXfGeY5kfGmxbjDhd5NigQ>?		MmrPNkBpenN?	NXqyc2pGUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDteZRidnRiYYX0c5Bpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDicIF{fCClZXzsd{Bi\nSncjCyJIhzeyCkeTDlcIVkfHKxY3jlcYltfW2rbnXzZ4Vv[2VuIFnDOVAhRSByLkCwNFgh\|ryPLh?=	M{GyO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkW0OFA5Lz5zOU[1OFQxQDxxYU6=
RS4-11	M1O4WmZ2dmO2aX;uJIF{e2G7		M2LhRlIhcHK\|	MkjtTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCrbjDoeY1idiCUU{StNVEh[2WubIOgZYZ1\XJiMjDodpMh[nliZXzlZ5Rzd2OqZX3pcJVucW6nc3PlcoNmKGG\|c3H5MEBKSzVyIE2gNE4xODFzIN88UU4>	MlLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl4NUS0NFgoRjF7NkW0OFA5RC:jPh?=
AML	MVzGeY5kfGmxbjDhd5NigQ>?			MnvsTY5pcWKrdHnvckBw\iCITGSzJIF2fG:yaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hSU2OIHPlcIx{KGm\|b3zheIVlKG[{b32gdoVt[XC\|ZXSgZYN2fGVibYnlcI9q\CCuZYXr[Y1q[SCyYYTp[Y51KGK7IGfld5Rmem5iYnzveJRqdmduIFnDOVAhRSByLkCwNkDPxE1w	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTZ3NESwPEc,OTl4NUS0NFg9N2F-
RS4-11	MXfGeY5kfGmxbjDhd5NigQ>?		NHn4VVUzKGi{cx?=	NX:5No9kUW6qaXLpeIlwdiCxZjDGUHQ{KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODB2MjFOwG0v	M{[4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkW0OFA5Lz5zOU[1OFQxQDxxYU6=
MV4-11	MkHIRY51cXS3bX;yJIF{e2G7	NE\mU4cyOCCvZz;r[y=>	M1rWcFYxKGSjeYO=	M32wVWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{B5\W6xZ4Lh[pRm\CCvb4Xz[UBud2SnbDDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKHKnZ4Lve5RpKGG2IHH0JFExKG2pL3vnMEBxdyB4MDDkZZl{KHCxc4SgeJJm[XSvZX70	NUO0Z4xCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
MV4-11	MkHuRY51cXS3bX;yJIF{e2G7	NUHQR\|lnOSCvZz;r[{9l[Xl?	NETKW4o{OCCmYYnz	MX7BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhdW:3c3WgZo9v\SCvYYLyc5ch\W6pcnHmeI1mdnRibX;k[Ywh[XO\|ZYPz[YQh[XNiaX7jdoVie2VibX;1d4UhdGmoZTDzdIFvKGG2IEGgcYcwc2dxZHH5MEBxdyCob4KgN\|Ah\GG7czDt[YF{fXKnZDDvckBl[XliN{egdI9{fCCmb4Pl	NU\iTIRFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm2OVQ1ODhpPkG5OlU1PDB6PD;hQi=>
MV4-11	MojIRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHzqXlg4OiCqcoO=	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2YND2xNUBk\WyuczDh[pRmeiB5MjDodpMh[nliY3XscEB1cXSncj3icJVmKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD6wNFA2PiEQvF2u	NFOxdm89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUe1OFE6QSd-MUm3OVQyQTl:L3G+
HEK293	MoDiSpVv[3Srb36gZZN{[Xl?			NFLDc29DcW6maX7nJIFn\mmwaYT5JJRwKE[OVEOgZ4F1[Wy7dHnjJIRwdWGrbjDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHL5JINwdXCndHn0bZZmKGKrbnTpcoch[XO\|YYmsJGtlKD1iMD6wNFE3KM7:TT6=	MkS2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	MYDBcpRqfHWvb4KgZZN{[Xl?	NVTsUFVVOSCvZz;r[y=>	NYjJd\|JJOjhiZHH5dy=>	MnXxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIIT1cY9zKGe{b4f0bEBifCBzIH3nM4toNCCybzDRSEBnd3JiMkig[IF6eyCvZXHzeZJm\CCmdYLpcoch\G:\|aX7nJJBmemmxZB?=	MlnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	M{G3VmFvfGm2dX3vdkBie3OjeR?=	M{i0WlMhdWdxa3e=	NUTHdXZwOjhiZHH5dy=>	MVfBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgfIVvd2e{YX\0[YQhcW5iYYTofY1q[yCwdXTlJI1wfXOnIHHzd4V{e2WmIHHzJJR2dW:{IHfyc5d1cCC{ZXfy[ZN{cW:wIHH0JFMhdWdxa3esJJBwKFGGIH\vdkAzQCCmYYnzJI1m[XO3cnXkJIFnfGW{IHTvd4lv\yCyZYLpc4Q>	M3\ONFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{W0NVk6Lz5zOUe1OFE6QTxxYU6=
MV4-11	M2Xpe2FvfGm2dX3vdkBie3OjeR?=	NVLsc5czOTBibXevb4c>	MXOyPEBl[Xm\|	NYLoeW12SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KHinbn;ndoFnfGWmIHnuJIF1cHmvaXOgcpVl\SCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigdoVoemW\|c3nvckBifCBzMDDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiYX\0[ZIh\G:\|aX7nJJBmemmxZB?=	MljWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	MoPoRY51cXS3bX;yJIF{e2G7	NH7aXGw{KG2pL3vn	NESzfmIzQCCmYYnz	MnXsRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjD0eY1weiC4b3z1cYUh[XRiMzDt[{9s\yxicH:gVWQh\m:{IEK4JIRigXNibXXhd5Vz\WRiYX\0[ZIh\G:\|aX7nJJBmemmxZB?=	MkXOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl5NUSxPVkoRjF7N{W0NVk6RC:jPh?=
MV4-11	MnTqRY51cXS3bX;yJIF{e2G7	MWOxNEBu\y:tZx?=	NUTET5FNOjhiZHH5dy=>	MnGxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIHH0bJlucWNiboXk[UBud3W\|ZTDhd5Nme3OnZDDhd{B{fXCycnXzd4lwdiCxZjD0eY1weiC4b3z1cYUh[XRiMUCgcYcwc2duIIDvJHFFKG[xcjCyPEBl[Xm\|IH3lZZN2emWmIHHmeIVzKGSxc3nu[{Bx\XKrb3S=	NYW1WllnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MV4-11	NGWydWtCdnSrdIXtc5Ih[XO\|YYm=	Mnm4NVAhdWdxa3e=	NU\6bo5VOjhiZHH5dy=>	NILMR4hCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMhgGWwb3fyZYZ1\WRiaX6gZZRpgW2rYzDueYRmKG2xdYPlJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geJVud3JiZ4Lve5RpKGG2IEGwJI1oN2upLDDwc{BSTCCob4KgNlgh\GG7czDt[YF{fXKnZDDh[pRmeiB\|MjDkZZl{KHCxc4Tkc5Nm	NX;aTFlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3OVQyQTlpPkG5O\|U1OTl7PD;hQi=>
MOLM13	NVnTSWhUSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			M2LvcWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTV;MUVE{KGOnbHzzJIV5eHKnc4PpcochTkyWMz3JWGQhdXW2YX70MEBIUTVyIE2gNE4xODRizszNMi=>	M4[zcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{K2PVMyLz5{MkeyOlk{OTxxYU6=
MV411	M4PhWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M2W2UlQ5KGi{cx?=	NXjo[5B1T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVZ2MUGgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiR1m1NEA:KDNwM{Gg{txONg>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFyOEC3PUc,OjVzMEiwO\|k9N2F-
THP1	NYfieHFGT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWK0PEBpenN?	NImzTmVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBVUFBzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEeLNUCgQUA2NjV5NDFOwG0v	MlrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEiwO\|koRjJ3MUC4NFc6RC:jPh?=
HL60	Mnz4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Ml:yOFghcHK\|	NIXldnBIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBJVDZyIHPlcIx{KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEeLNUCgQUA5NjBzNDFOwG0v	MmL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMEiwO\|koRjJ3MUC4NFc6RC:jPh?=
32D	NIi3RoZHfW6ldHnvckBie3OjeR?=		M{[2XVczKGi{cx?=	M{O1VWlvcGmkaYTpc44hd2ZiaIXtZY4hTkyWMzDJWGQhdXW2YX70JIV5eHKnc4Pl[EBqdiCvb4Xz[UA{OkRiY3XscJMh[XO\|ZYPz[YQh[XNiY3XscEBoem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgUXRUKGG\|c3H5MEBIUTVyIE2gNE4xODByMTFOwG0v	NF;3Uno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MV4-11	NVv3fVhlTnWwY4Tpc44h[XO\|YYm=		NGrsUYE4OiCqcoO=	M3TxNWlvcGmkaYTpc44hd2ZiRlzUN{BKXERiaH;tc5p6\2:3czDteZRidnRiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IECuNFA{KM7:TT6=	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MUCyN{c,OjZyOEGwNlM9N2F-
MOLM-13	M{O1O2Z2dmO2aX;uJIF{e2G7		M4DiWFczKGi{cx?=	MUPJcohq[mm2aX;uJI9nKE[OVEOgTXRFKGindHXyc5p6\2:3czDteZRidnRiaX6gbJVu[W5iTV;MUU0yOyClZXzsd{Bie3Onc4Pl[EBieyClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDNWHMh[XO\|YYmsJGdKPTBiPTCwMlAxPCEQvF2u	Mn\EQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
32D	MUDGeY5kfGmxbjDhd5NigQ>?		NFjBboI4OiCqcoO=	MVHJcohq[mm2aX;uJI9nKGS{dXegdoV{cXO2YX70JIh2dWGwIF\MWFMhUVSGIFS4N\|V[KG23dHHueEBmgHC{ZYPz[YQhcW5ibX;1d4UhOzKGIHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VWyCjc4PhfUwhT0l3MDC9JFAvODF4IN88UU4>	M{fLfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEixNFI{Lz5{NkC4NVAzOzxxYU6=
32D	Mly1SpVv[3Srb36gZZN{[Xl?		M1HFU\|czKGi{cx?=	Mn\ITY5pcWKrdHnvckBw\iCmcoXnJJJme2m\|dHHueEBpfW2jbjDGUHQ{KEmWRDDEPFM2XiCvdYThcpQh\XiycnXzd4VlKGmwIH3veZNmKDN{RDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBOXFNiYYPzZZktKEeLNUCgQUAxNjB{NzFOwG0v	NGPxV289[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
Sf9	MXnGeY5kfGmxbjDhd5NigQ>?		NH7VOnk1KGi{cx?=	M{jpZmlvcGmkaYTpc44hd2Zid3ns[EB1gXCnIFfTWE11[WepZXSgSmxVOyCtaX7hd4Uh\G:vYXnuJEh[PTZ5IITvJHM6QTNrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKGmwc3XjeEBU\jliY3XscJMhfXOrbnegTIVzOiCyZYD0bYRmKGG\|IIP1ZpN1emG2ZTDh[pRmeiB2IHjyd{BjgSCNaX7hd4UuT2yxIHHzd4F6NCCLQ{WwJF0hOC5yNkmg{txONg>?	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MUCyN{c,OjZyOEGwNlM9N2F-
32D	NETjdXRHfW6ldHnvckBie3OjeR?=		MkXkO\|IhcHK\|	NGLrVm9KdmirYnn0bY9vKG:oIHTyeYchemW\|aYP0ZY51KGi3bXHuJGZNXDNiSWTEJGQ5OzWIIH31eIFvfCCneIDy[ZN{\WRiaX6gcY92e2ViM{LEJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WUzDhd5NigSxiR1m1NEA:KDBwMUWg{txONg>?	NGrpOpM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
32D	NYDORZB2TnWwY4Tpc44h[XO\|YYm=		MXS3NkBpenN?	M1fRTGlvcGmkaYTpc44hd2ZiZIL1[{Bz\XOrc4ThcpQhcHWvYX6gSmxVOyCLVFSgSlY6OUxibYX0ZY51KGW6cILld5Nm\CCrbjDtc5V{\SB\|MlSgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwJF0hOC5{MjFOwG0v	NH3xOoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
Sf9	M2TuXGZ2dmO2aX;uJIF{e2G7		MoC4NVIxKG2rboO=	MY\Jcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFfTWE11[WepZXSgWmVITlJ{IHvpcoF{\SCmb33hbY4hMFZ5OEmgeI8hXjF\|NU[pJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKGmwc3XjeEBU\jliY3XscJMhfXOrbnegdI9tgUeudUS6WJlzKHCncITp[IUh[XNic4Xid5Rz[XSnIHHmeIVzKDF{MDDtbY5{KGK7IFvpcoF{\S2JbH:gZZN{[XluIFnDOVAhRSByLkSzJO69VS5?	MnrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
RS4:11	NX60ZZM6TnWwY4Tpc44h[XO\|YYm=		M3TDVFczKGi{cx?=	NEXXRnVKdmirYnn0bY9vKG:oIIfpcIQhfHmyZTDoc41wgnmpb4XzJGZNXDNiaX6gbJVu[W5iUmO0PlEyKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHyg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IF3UV{Bie3OjeTygS2k2OCB;IEKuNkDPxE1w	NGLiV2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NVAzOyd-Mk[wPFExOjN:L3G+
MV4-11	MULBcpRqfHWvb4KgZZN{[Xl?	MlLPNVAhdWdxa3e=	Ml7YOFgh\GG7cx?=	Mn:xRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTW[0MVEyKGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO\|ZXSgZZMhfHWvb4KgdoVoemW\|c3nvckBifCBzMDDt[{9s\yxicH:gdYQh[WSvaX7pd5RmemWmIH;uJIRigSBzIITvJFUhdWWjc4Xy[YQh\HW{aX7nJFQ5KGSjeYOgdI9{fCCuYYP0JIRwe2V?	MnfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
MV4-11	NV;tSXp7SW62aYT1cY9zKGG\|c3H5	MX[xNEBu\y:tZx?=	NHHNbno1QCCmYYnz	M{TzV2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueYRmKG2xdYPlJIF{e2W\|c3XkJIF{KHS3bX;yJJJm\3Knc4Ppc44h[XRiMUCgcYcwc2duIIDvJJFlKGGmbXnubZN1\XKnZDDvckBl[XliODD0c{AyOiCvZXHzeZJm\CCmdYLpcochPDhiZHH5d{Bxd3O2IHzhd5Qh\G:\|ZR?=	MlLKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOEGwNlMoRjJ4MEixNFI{RC:jPh?=
MV4-11	Mne4R5l1d3SxeHnjbZR6KGG\|c3H5		MmfaO\|IhcHK\|	Mnq0R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGmwY4XiZZRm\CCob4KgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODByNkig{txONg>?	MoTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNEKzNVcoRjJ4MUSyN\|E4RC:jPh?=
Sf21	NIS1UIVHfW6ldHnvckBie3OjeR?=		MnixNVUhdWmwcx?=	NYiwUXZuUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDGUHQ{KGW6cILld5Nm\CCrbjDpcpNm[3RiU3[yNUBk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEG1JI1qdnNiZn;scI94\WRiYomgdI9tgSiJbIW6WJlzMSC\|dXLzeJJifGViYXTkbZRqd25iZn;yJFMxKG2rboOgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN{UG3BWHAh[nliVGKtSnJGXCCjc4PhfUwhUUN3MDC9JFAvODJ4MEig{txONg>?	M3O4cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUi3PFYxLz5{N{G4O\|g3ODxxYU6=
MV4-11	NEHO[I1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NGnINmc1QCCqcoO=	MkXrS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGW6cILld5NqdmdiRlzUN{1KXERiYX\0[ZIhPDhiaILzJIJ6KFiWVDDhd5NigSxiR1m1NEA:KDFwMUCzJO69VS5?	NVPXb4d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
HL60	MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NID4[3M1QCCqcoO=	M1jCS2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhNPjBiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViRlzUMVMh[W[2ZYKgOFghcHK\|IHL5JHhVXCCjc4PhfUwhT0l3MDC9JFEvPDh6IN88UU4>	Mle5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOEe4OlAoRjJ5MUi3PFYxRC:jPh?=
THP1	M2ra[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVe0PEBpenN?	MoPBS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gWGhROSClZXzsd{BmgHC{ZYPzbY5oKHerbHSgeJlx\SCITGStN{Bi\nSncjC0PEBpenNiYomgXHRVKGG\|c3H5MEBIUTVyIE2gNk4yOjVizszNMi=>	MkLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzOEe4OlAoRjJ5MUi3PFYxRC:jPh?=
K562	Mk\0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYHM[Y13PDhiaILz	NFP0b3RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBMPTZ{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBZXFRiYYPzZZktKEeLNUCgQUAzNjZ\|ODFOwG0v	NV\xVZpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexPFc5PjBpPkK3NVg4QDZyPD;hQi=>
Sf21	NU\kNVNlTnWwY4Tpc44h[XO\|YYm=		MYexNEBucW6\|	M1Pae2lvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJJdqdGRvdInw[UBHVFR\|IDi1OlQhfG9iZX7kJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgd4YzOSClZXzsd{B2e2mwZzDBZox1cWSnIHHzJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWF\|M2DdRXRRKGGodHXyJFExKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkCyOVUh\|ryPLh?=	NVTkWFNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwOFM4QTRpPkK4NFQ{Pzl2PD;hQi=>
Sf21	NFfib5pHfW6ldHnvckBie3OjeR?=		MXixNEBucW6\|	M2nW[2lvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDHV3QufGGpZ3XkJJJm[2:vYnnuZY51KGi3bXHuJJdqdGRvdInw[UBHVFR\|IDi1OlQhfG9iZX7kJJJme2mmdXXzLUBFQDN3WTDteZRidnRiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoMkGgZ4VtdHNidYPpcochSWKudHnk[UBieyC\|dXLzeJJifGViaX6gdJJme2WwY3Wgc4YhY2ejbX3hN\|NRZUGWUDDh[pRmeiBzMDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE4zOzV3IN88UU4>	NVHGbVVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiwOFM4QTRpPkK4NFQ{Pzl2PD;hQi=>
MV4-11	NFvLUGJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			NXPwc\|I4T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVVZ2LUGxJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRDDteZRidnRiYomgXHRVKGG\|c3H5MEBIUTVyIE2gNU4yODNizszNMi=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDB2M{e5OEc,OjhyNEO3PVQ9N2F-
THP1	MWXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?			NHTVdYdIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBVUFBzIHPlcIx{KGijcnLvdolv\yC5aXzkMZR6eGViRlzUN{BjgSC[VGSgZZN{[XluIFfJOVAhRSB{LkGyOUDPxE1w	MnrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhyNEO3PVQoRjJ6MESzO\|k1RC:jPh?=
BAF3	NVXJRmJVSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M{PCN\|czKGi{cx?=	MnXvRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2TyCvdYTheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMECwN{DPxE1w	M2TWe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	M3n2ZmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXi3NkBpenN?	MoPhRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2SSCvdYTheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMECwN{DPxE1w	NF3xOlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	Ml7yRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWq3NkBpenN?	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIF\MWFMuTDh\|NVigcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxODNizszNMi=>	NHG5XmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM13	NEPPUmlCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NYLJdmZiPzJiaILz	Mn34RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEJI12fGG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	NYDSR3pVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	Mne0RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1G4PFczKGi{cx?=	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiZYjwdoV{e2mwZzDUSWwu\nW\|ZXSgSmxVOyCtaX7hd4Uh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjByMEOg{txONg>?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	NVvvU3dbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M1i5UVczKGi{cx?=	Mly1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2ViCvdYTheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMECwN{DPxE1w	M2rlZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	MYjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MkL5O\|IhcHK\|	Ml7uRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPT1zNNVQh[2WubIOgbIFz[m:{aX7nJGZNXDNvSWTEJI12fGG2aX;uJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xODB\|IN88UU4>	M1\PW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	NEHDbWxCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MnfvO\|IhcHK\|	MmmwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRDDteZRifGmxbjDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNFAxOyEQvF2u	NFrYXlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MV4-11	MWnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYS3NkBpenN?	MnjCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPVkStNVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxODNizszNMi=>	NELWO5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
BAF3	MmLkRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MVW3NkBpenN?	M{LNS2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJHBFT0[UYXzwbIEufHKjboPmc5Ju\WRibX;1d4UhSkGIMzDj[YxteyCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMECwN{DPxE1w	M1HZSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	MlTBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M1;tZlczKGi{cx?=	MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDRkOgZ4VtdHNiaHHyZo9zcW6pIF\MWFMuTDh\|NWmgcZV1[XSrb36gZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlAxOiEQvF2u	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	M{GxVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MoP2O\|IhcHK\|	MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDQSGdHWmKndHGteJJidnOob4Lt[YQhdW:3c3WgRmFHOyClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFAvODB2NDFOwG0v	MlS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NUfkfngxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M3XZelczKGi{cx?=	NVHsSFA3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBud3W\|ZTDCRWY{KGOnbHzzJIhiemKxcnnu[{BHVFR\|LVS4N\|VXKG23dHH0bY9vKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOC5yMUGg{txONg>?	MkjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	M2P4emFvfGmycn;sbYZmemG2aY\lJIF{e2G7		Ml64O\|IhcHK\|	MlTGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2\GWuIH31eIF1cW:wIHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6wNVIh\|ryPLh?=	MmPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9	NGLm[WJHfW6ldHnvckBie3OjeR?=		MXqxJIhz	NUP1cFFGUW6qaXLpeIlwdiCxZjDoeY1idiCPVkStNVEh[2WubIOt[IVzcX[nZDDIbZMufGGpZ3XkJGZNXDNiSWTEJI12fGGwdDCoOVY1KHSxIEm5N{Bz\XOrZIXld{kh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJJNnQSClZXzsd{B2e2mwZzDwc4x6KCh2OkGgS4x2NCCWeYKpJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JGFFWC2JbH:gb4lv[XOnIHHzd4F6NCCLQ{WwJF0hOC5yMU[4JO69VS5?	M{XoRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	NFq4d25CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVzFSWt7PzJiaILz	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGTFUE1nfXOnZDDjT2lVNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkCxO{DPxE1w	NULYN\|E5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn;1O\|IhcHK\|	NHHYZnNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHRGVC2odYPl[EBEW0ZzUj30doFve2[xcn3l[EBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4xOjRizszNMi=>	M3[zPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	M3OwWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NV;GRXVlPzJiaILz	MlvVRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEQV[zJINmdGy\|IHjhdoJwemmwZzDGUHQ{NUmWRD3EPFM2YSCvdYTheIlwdiCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMEK4JO69VS5?	Mnq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Sf9	MULGeY5kfGmxbjDhd5NigQ>?		NGLvZW8yKGi{	M1vtR2lvcGmkaYTpc44hd2ZiaIXtZY4hUEx4MDDj[Yxtey2mZYLpeoVlKEircz30ZYdo\WRiRlzUN{ApPTZ2IITvJFk6OyC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{KGmwZnXjeIVlKHOoOTDj[YxteyC3c3nu[{Bxd2y7IDi0PlEhT2y3LDDUfZIqKGG\|IIP1ZpN1emG2ZTDh[pRmeiBzIHjyJIJ6KEGGUD3HcI8hc2mwYYPlJIF{e2G7LDDJR\|UxKD1iMD6wN\|A1KM7:TT6=	MlvwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
BAF3	NInZNopCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M3;tclczKGi{cx?=	M3;3RmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlHGN{Bk\WyuczDoZZJjd3KrbnegSmxVOy2LVFStSFg{PUlibYX0ZZRqd25iYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkC1OkDPxE1w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
BAF3	MoTBRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFvu[XA4OiCqcoO=	M1fKR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJGRFWjJvdILhcpNnd3KvZXSgcY92e2ViQlHGN{Bk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygS2k2OCB;IECuNVEh\|ryPLh?=	M17OV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
BAF3	NXjEWJU3SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXW3NkBpenN?	NGjCepRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JHRGVC2odYPl[EBFTFJzLYTyZY5{\m:{bXXkJI1wfXOnIFLBSlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGdKPTBiPTCwMlEzKM7:TT6=	NHjJUXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
CMK	MnnmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV23NkBpenN?	NXm4dJJJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDUWsh[2WubIOg[ZhxemW\|c3nu[{BHVFR\|IHvpcoF{\SCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMUKg{txONg>?	NWXaSIVORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	NYXKSYh1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NVzCW4NJPzJiaILz	M3\VdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgWGVNNW[3c3XkJHJGXC22cnHud4Zwem2nZDDtc5V{\SCEQV[zJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDHTVUxKD1iMD6xN{DPxE1w	NIK0fVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
HL60	NUS4fHRwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NUnlVmxXPzJiaILz	NIP1fXRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjMOlAh[2WubIOg[ZhxemW\|c3nu[{BHVFR\|IHvpcoF{\SCjZoTldkA4OiCqcoOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiR1m1NEA:KDBwMUOg{txONg>?	NYXFbmpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	NELHWoJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXO3NkBpenN?	NX;Ic3Z{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBVTUxvZoXz[YQhTkyWND30doFve2[xcn3l[EBud3W\|ZTDCRWY{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gNE4zPyEQvF2u	NUP1WFBjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	M3\rbGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2nwc\|czKGi{cx?=	NFz3elBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBSlMh[2WubIOgbIFz[m:{aX7nJGZNXDNvS{[2N3EhdXW2YYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjN5IN88UU4>	NXPNcZZCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
BAF3	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4XSSVczKGi{cx?=	MluwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDUSWwu\nW\|ZXSgUGNMNXS{YX7z[o9zdWWmIH3veZNmKEKDRkOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gZZN{[XluIFfJOVAhRSByLkSg{txONg>?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
U937	NFzVRXhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{jYXFczKGi{cx?=	M2H4NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUmzO{Bk\WyuczDlfJBz\XO\|aX7nJGZNXDNia3nuZZNmKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCJSUWwJF0hOS5{IN88UU4>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDl3NkmyN{c,Ojh7NU[5NlM9N2F-
SKM1	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M4rPelczKGi{cx?=	MUHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONTUGgZ4VtdHNiZYjwdoV{e2mwZzDGUHQ{KGurbnHz[UBi\nSncjC3NkBpenNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhT0l3MDC9JFEvOyEQvF2u	MoPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
NB4	MoP1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MV63NkBpenN?	MWXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6ENDDj[YxteyCneIDy[ZN{cW6pIF\MWFMhc2mwYYPlJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKtS4xwKGG\|c3H5MEBIUTVyIE2gO{4{KM7:TT6=	NUCxfHMxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MOLM13	MVjD[YxtKGO7Y3zlJIF{e2G7	MmHiNVAxKG6P	MWmxNkBpenN?	NILTWIpE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBOV0yPMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFewM2cyKHCqYYPlJIF1KDFyMDDuUUBi\nSncjCxNkBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZzDiZZNm\C2IQVPTJIFv[Wy7c3nz	M1exTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	M3nTVWNmdGxiY4njcIUh[XO\|YYm=	MVixNFAhdk1?	MkTNNVIhcHK\|	NX7j[oRPS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVU:OTUG0JINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCBzMECgcm0h[W[2ZYKgNVIhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRvRlHDV{BidmGueYPpdy=>	M{nwSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM13	M3\l[mFxd3C2b4Ppd{Bie3OjeR?=	M{TSbVExOCCwTR?=	NFXiUVYyOiCqcoO=	NVn2bZk4UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTNiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gVGFTWCCjdDCxNFAhdk1iYX\0[ZIhOTJiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	NULxUZlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MV4-11	NW\UXJhpSXCxcITvd4l{KGG\|c3H5	Mne4NVAxKG6P	NUDQVGxKPDhiaILz	NHzWbYZKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|IHnuJIh2dWGwIF3WOE0yOSClZXzsd{Bie3Onc4Pl[EBieyClbHXheoFo\SCxZjDQRXJRKGG2IEGwNEBvVSCjZoTldkA1QCCqcoOgZpkhcW2vdX7vZoxwfHSrbnegcYV1cG:m	NFHXe\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM13	M{HqNGFxd3C2b4Ppd{Bie3OjeR?=	M2m5RlExOCCwTR?=	NHjIcFQyOiCqcoO=	NVPKV2hCUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTNiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gZ4F{eGG\|ZT2zJIF1KDFyMDDuUUBi\nSncjCxNkBpenNiYomgbY1ufW6xYnzveJRqdmdibXX0bI9l	NFixeFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm1OlkzOyd-Mki5OVY6OjN:L3G+
MOLM14	NGC0fZNCeG:ydH;zbZMh[XO\|YYm=	NY\1cGFqOTByIH7N	MVuyOEBpenN?	NWO1[41MUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDNU2xOOTRiY3XscJMh[XO\|ZYPz[YQh[XNiY3zlZZZi\2Vib3[gVGFTWCCjdDCxNFAhdk1iYX\0[ZIhOjRiaILzJIJ6KGmvbYXuc4Jtd3S2aX7nJI1mfGixZB?=	M1z3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUW2PVI{Lz5{OEm1OlkzOzxxYU6=
MOLM14	M3noO2Fxd3C2b4Ppd{Bie3OjeR?=	M3TITlExOCCwTR?=	MXyyOEBpenN?	M3TiSGlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTV;MUVE1KGOnbHzzJIF{e2W\|c3XkJIF{KGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDheEAyODBibl2gZYZ1\XJiMkSgbJJ{KGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	NYjDZlRJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki5OVY6OjNpPkK4PVU3QTJ\|PD;hQi=>
MV4-11	NH7COHJCeG:ydH;zbZMh[XO\|YYm=	NV3tdIttOTByIH7N	NY\3UlJVPDhiaILz	M2DHXmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF{e2W\|c3XkJIF{KGOuZXH2ZYdmKG:oIHPhd5Bie2VvMzDheEAyODBibl2gZYZ1\XJiNEigbJJ{KGK7IHntcZVvd2Kub4T0bY5oKG2ndHjv[C=>	Ml\vQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
MV4-11	NHnWcGZE\WyuIHP5Z4xmKGG\|c3H5	MUixNFAhdk1?	NFPlXlkyOiCqcoO=	NXjWbWFpS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDHNE9IOSCyaHHz[UBifCBzMECgcm0h[W[2ZYKgNVIhcHK\|IHL5JJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnegZoF{\WRvRlHDV{BidmGueYPpdy=>	MkDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7NU[5NlMoRjJ6OUW2PVI{RC:jPh?=
Saos-2	NILOVHZyUFSVIHHzd4F6			NVO2VYVbeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	M{\JTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MVfxTHRUKGG\|c3H5			M4fxXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	M1fB[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12	NGHkbHpyUFSVIHHzd4F6			NYn1THlGeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvMUKgZ4VtdHN?	M4jsTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5	NUm5OGZmeUiWUzDhd5NigQ>?			M1\tOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGxCVi13IHPlcIx{	MkPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NVrWfG01eUiWUzDhd5NigQ>?			M1HSPZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGRCV1liY3XscJM>	MnTlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NVrTRYRyeUiWUzDhd5NigQ>?			NXOyeVBReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	MWnxTHRUKGG\|c3H5			M2HLZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGE3PzNiY3XscJMq	NETPTpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	MknydWhVWyCjc4PhfS=>			M2XCXZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	MofZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
U-2 OS	M3z0NZFJXFNiYYPzZZk>			NYTpTox3eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhXS1{IF;TJINmdGy\|	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NVniPW94eUiWUzDhd5NigQ>?			NGjVW45yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBQUFNvNUCgZ4VtdHN?	Mnq3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	M2rPW5FJXFNiYYPzZZk>			NYnFRmQ5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NUXmfYtDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MV\xTHRUKGG\|c3H5			NXe1O\|I6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM>	NIrjN5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NGXTeWZyUFSVIHHzd4F6			MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	MlH1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MkP0dWhVWyCjc4PhfS=>			MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NFXUO5hyUFSVIHHzd4F6			M1i4bpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>?	NUW4fI1NRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	NUHGbGRreUiWUzDhd5NigQ>?			NWLaepdKeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?=	NIfRbYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	Ml\NdWhVWyCjc4PhfS=>			M3PTfpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN?	NHf5NIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	NGjoZ5VyUFSVIHHzd4F6			Ml3GdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWGM{OiClZXzsdy=>	M4\nflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MOLM13	M4H3emdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NGfybmo4OiCqcoO=	NHe4UnVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOV0yPMUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGOjbHPlbY4hSU1iZInlMYJie2WmIH\seY9z\XOlZX7j[UBie3OjeTygS2k2OCB;IECuNFAzKM7:TT6=	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
MV4-11	NUn5WWROT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVm3NkBpenN?	MlfPS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUXY1NTFzIHPlcIx{KGGodHXyJFczKGi{czDifUBk[WylZXnuJGFOKGS7ZT3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFfJOVAhRSByLkCwN{DPxE1w	NHPOemM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
BA/F3	MonDSpVv[3Srb36gZZN{[Xl?		NH\PO5k4OiCqcoO=	MUXJcohq[mm2aX;uJI9nKE[OVEOgTXRFKG23dHHueEApfW6tbn;3ckBwemmpaX6pJJRz[W6\|ZnXjeIVlKGmwIH3veZNmKEKDL1[zJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEeyJIhzeyCkeTDjZYxk\WmwIFHNJIR6\S2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEeLNUCgQUAxNjByNzFOwG0v	M3PPUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
Sf9	NH:zV29HfW6ldHnvckBie3OjeR?=			NUD1WIhxUW6qaXLpeIlwdiCxZjDOMZRmem2rbnHsJGdUXC:KaYO2MYZ2e2WmIILlZ49u[mmwYX70JIh2dWGwIF\MWFMhMFJ3N{GgeI8hWzl7MzDy[ZNq\HWnczmgTXRFKG23dHHueEBmgHC{ZYPz[YQhcW5iU3[5JIlve2WldDDj[YxteyC3c3nu[{Bxd2y7IDjBcIEtT2y3LFz5d{xVgXJrIE[6Nlo2QjFiaInkdo9jem:vaXTlJIF{KHO3YoP0doF1\SCrbjDwdoV{\W6lZTDv[kBc\2GvbXGtN\|NRZUGWUDygTWM2OCB;IECuNFEh\|ryPLh?=	Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
Sf9	NUDTSXh1TnWwY4Tpc44h[XO\|YYm=			NIjPS\|ZKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygS3NVN0irc{[t[pV{\WRicnXjc41jcW6jboSge4lt\CC2eYDlJIh2dWGwIF\MWFMhMFJ3N{GgeI8hWzl7MzDy[ZNq\HWnczmg[ZhxemW\|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMhfXOrbnegdI9tgSBqQXzhMGdtfSyOeYOsWJlzMSB4OkK6OVoyKGi7ZILvZpJwdWmmZTDhd{B{fWK\|dILheIUhcW5icILld4Vv[2Vib3[gX4didW2jLUOzVH1CXFBuIFnDOVAhRSByLkCzOkDPxE1w	NGfGNlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
Kasumi-1	M1TBb2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MkiwO\|IhcHK\|	MY\Hdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDLZZN2dWlvMTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[2GuY3XpckBCVSCmeXWtZoF{\WRiZnz1c5Jme2OnbnPlJIF{e2G7LDDHTVUxKD1iMD6wOlQh\|ryPLh?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZ5MkC0PUc,Ojl4N{KwOFk9N2F-
Sf9	M{K5UmZ2dmO2aX;uJIF{e2G7			NHrjSmNKdmirYnn0bY9vKG:oIF6teIVzdWmwYXygS3NVN0irc{[t[pV{\WRicnXjc41jcW6jboSgbJVu[W5iRlzUN{ApWjV5MTD0c{BUQTl\|IILld4llfWW\|KTDEPFM2YSCvdYThcpQh\XiycnXzd4VlKGmwIGPmPUBqdnOnY4SgZ4VtdHNidYPpcocheG:ueTCoRYxiNEeudTzMfZMtXHm{KTC2PlI7PTpzIHj5[JJw[nKxbXnk[UBieyC\|dXLzeJJifGViaX6gdJJme2WwY3Wgc4YhY2ejbX3hMVM{WF2DVGCsJGlEPTBiPTCwMlE{PiEQvF2u	NIrrb3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
BA/F3	NYjPSmZxT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NIDkcJI4OiCqcoO=	MWfHdo94fGhiaX7obYJqfGmxbjDv[kBud3W\|ZTDCRU9HOyClZXzsd{Bi\nSncjC3NkBpenNiYomgZ4Ft[2WrbjDBUUBlgWVvYnHz[YQh\my3b4Lld4NmdmOnIHHzd4F6NCCJSUWwJF0hOS52NUKg{txONg>?	M4HCSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	M3rzU2Z2dmO2aX;uJIF{e2G7	M37ve\|AvODFidH:gNVAxKG6P	NH3Tb3cyKGi{	NEXxU2pKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iQVvUJJBpd3OyaH;yfYxifGmxbjDheEBUPDd\|IHH0JFAvODFidH:gNVAxKG6PIHHmeIVzKDFiaIKgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NUTzUo43RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	NHLvfopHfW6ldHnvckBie3OjeR?=	MWSwMlAyKHSxIEGwNEBvVQ>?	NWq2enZ6OSCqch?=	M3XjcmlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCPRVuxM\|IheGixc4Doc5J6dGG2aX;uJIF1KFN{MUevNlIyKGG2IECuNFEhfG9iMUCwJI5OKGGodHXyJFEhcHJiYomgbY1ufW6xYnzveEBidmGueYPpdy=>	M36zVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkeyNFQ6Lz5{OU[3NlA1QTxxYU6=
MV4-11	NYPBdGR5TnWwY4Tpc44h[XO\|YYm=	MVWxJI5O	NFz5bXQyKGi{	NILISlRKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIHH0JHk2QDlxNUmxJIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjdDCxJI5OKGGodHXyJFEhcHJiYomgbY1ufW6xYnzveEBidmGueYPpdy=>	NIPibZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[3NlA1QSd-Mkm2O\|IxPDl:L3G+
MV4-11	NV3HPINDTnWwY4Tpc44h[XO\|YYm=	M2LqSFEhdk1?	NET6bnIyKGi{	MkLaTY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQh[XW2b4Doc5NxcG:{eXzheIlwdiCjdDDZPFQzKGmwIHj1cYFvKE2YND2xNUBk\WyuczDheEAyKG6PIHHmeIVzKDFiaIKgZpkhcW2vdX7vZoxwfCCjbnHsfZNqew>?	NX\6XIpyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	MkXzSpVv[3Srb36gZZN{[Xl?	NVKyeJlrOC5yMTD0c{AyODBibl2=	NWfHVoRFOSCqch?=	M1jpbmlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGmwIHj1cYFvKE2YND2xNUBk\WyuczDhd5Nme3OnZDDhd{Bl\WO{ZXHz[UBqdiCVVFHUOUBxcG:\|cHjvdplt[XSrb36gZZQhYTZ7NDDheEAxNjBzIITvJFExOCCwTTDh[pRmeiBzIHjyJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	MnzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
MV4-11	M2i2T2Z2dmO2aX;uJIF{e2G7	MX2wMlAyKHSxIEGwNEBvVQ>?	NEXwbFEyKGi{	NGLCeYxKdmirYnn0bY9vKG:oIF\MWFMhUVSGIH31eIFvfCCrbjDoeY1idiCPVkStNVEh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iRWLLNU8zKHCqb4PwbI9zgWyjdHnvckBifCCWMkCyM3kzODRiYYSgNE4xOSC2bzCxNFAhdk1iYX\0[ZIhOSCqcjDifUBqdW23bn;icI91KGGwYXz5d4l{	NWH6bmh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm2O\|IxPDlpPkK5OlczODR7PD;hQi=>
MV4-11	MnXISpVv[3Srb36gZZN{[Xl?	MlruNVAhdWdxa3e=	MVGyOEBpenN?	M3vOS2lvKH[rdn:gbY5pcWKrdHnvckBw\iCITGSzJGlVTCCvdYThcpQhcW5iaIXtZY4hVVZ2LUGxJINmdGy\|IIjlco9oemGodHXkJIlvKGG2aIntbYMhdnVxboWgcY92e2ViYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHH0JHk3QTRiYYSgNVAhdWdxa3esJIlxKGGodHXyJFI1KGi{czDifUBqdW23bn;icI91KG2ndHjv[EBz\WyjdHn2[UB1dyClb370do9t	MlLiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4N{KwOFkoRjJ7NkeyNFQ6RC:jPh?=
MV4-11	M4\pemZ2dmO2aX;uJIF{e2G7	MVmwMlEhfU1?	NF;3fZc1KGi{cx?=	M2XmSmlvcGmkaYTpc44hd2ZiRlzUN{BqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEGNVDDwbI9{eGixconsZZRqd25iYYSgV4VzPDd\|IILld4llfWViYYSgNE4yKHWPIHHmeIVzKDRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NH3zXlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUi5OFk1PCd-Mkm4PVQ6PDR:L3G+
MV4-11	NGDo[mFHfW6ldHnvckBie3OjeR?=	NF[0RVYxNjFidV2=	MVq0JIhzew>?	MnqyTY5pcWKrdHnvckBw\iCITGSzJIlvKGi3bXHuJG1XPC1zMTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hW1SDVEWgdIhwe3Cqb4L5cIF1cW:wIHH0JHR6ejZ7NDDy[ZNq\HWnIHH0JFAvOSC3TTDh[pRmeiB2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm\|aYO=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTh7NEm0OEc,Ojl6OUS5OFQ9N2F-
MV4-11	NV7GXXRmTnWwY4Tpc44h[XO\|YYm=	M1zDdVAvOSC3TR?=	NVXvdoJFPCCqcoO=	M4fDRmlvcGmkaYTpc44hd2ZiRlzUN{BqdiCqdX3hckBOXjRvMUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKEWUS{GvNkBxcG:\|cHjvdplt[XSrb36gZZQhXGi{MkCyM3R6ejJyNDDy[ZNq\HWnczDheEAxNjFidV2gZYZ1\XJiNDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz	NYfXR3R1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4PVQ6PDRpPkK5PFk1QTR2PD;hQi=>
MV4-11	M2PqSGZ2dmO2aX;uJIF{e2G7	MYGwMlEhfU1?	NG\UO2k1KGi{cx?=	NEX3OnBKdmirYnn0bY9vKG:oIF\MWFMheGixc4Doc5J6dGG2aX;uJIF1KFS7ckW4PU82QTFicnXzbYR2\XNiaX6gbJVu[W5iTW[0MVEyKGOnbHzzJIF1KDBwMTD1UUBi\nSncjC0JIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM>	NV:0fGhzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm4PVQ6PDRpPkK5PFk1QTR2PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-STAT5 / STAT5 / β-catenin / p-AKT / AKT / p-ERK / ERK / p-S6 / S6; PubMed: 28625976 Cancer Res Western blot analysis of AC220 treated MV4-11 cells. Cells were starved for overnight and treated with AC220 at indicated concentrations. Cells were harvested after 2 hours treatment and lysed. Then western blots analysis was performed. The quantification of bands are shown below the gel. phospho-FLT3 / FLT3; PubMed: 22875611 Haematologica (B) The same cells were also harvested for Western blot analysis after treatment for 90 min with different concentrations of AC220. The phosphorylation of the different FLT3 proteins was determined using a phospho-FLT3 antibody.	28625976 22875611
Immunofluorescence	WGA / FLT3 ; PubMed: 28895560 Leukemia Immunofluorescence staining of FLT3-WT, FLT3 mutants or empty vector with or without AC220 treatment in transiently transfected U2OS cells. WGA (wheat germ agglutinin). Scale bar: 25 μm.	28895560
Growth inhibition assay	Cell viability; PubMed: 23967177 PLoS One K562/ABCB1 and K562/ABCG2 cells exhibit collateral sensitivity toquizartinib. K562, K562/ABCB1 and K562/ABCG2 cells were plated in the presence of quizartinib in increasing concentrations for 96 hours and viable cells were measured using the WST-1 assay.	23967177

In vivo

Oral administration of AC220 (10 mg/kg) induces time-dependent inhibition of FLT3 autophosphorylation in the FLT3-ITD–dependent MV4-11 tumor xenograft mouse model; the inhibition being 90% at 2 hours and 40% at 24 hours. AC220 significantly extends survival in a mouse model of FLT3-ITD AML with doses as low as 1 mg/kg given orally once a day. Treatment with AC220 at 10 mg/kg for 28 days results in rapid and complete regression of tumors in all mice with no tumor regrowth during the 60-day posttreatment period. AC220 displays more significant efficacy compared to sunitinib treatment which causes tumors to shrink slowly and resume growth immediately upon discontinuation of treatment in all but one of the mice. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Inhibition of FLT3 autophosphorylation: To measure inhibition of FLT3 autophosphorylation, MV4-11 or RS4;11 cells are cultured in low serum media (0.5% FBS) overnight and seeded at a density of 400 000 cells per well in a 96-well plate the following day. The cells are incubated with different concentrations of AC220 for 2 hours at 37 °C. To induce FLT3 autophosphorylation in RS4;11 cells, 100 ng/mL FLT3 ligand is added for 15 minutes after the 2-hour AC220 incubation. Cell lysates are prepared and incubated in 96-well plates precoated with a total FLT3 capture antibody. The coated plates are incubated with either a biotinylated antibody against FLT3 to detect total FLT3 or an antibody against phosphotyrosines to detect FLT3 autophosphorylation. In both cases, a SULFO-tagged streptavidin secondary antibody is used for electrochemiluminescence detection on the Meso Scale Discovery platform. The concentration of AC220 that inhibits FLT3-ITD or TLT3-WT autophosphorylation by 50% represents IC50 value
Cell Research:^[1]	- Collapse Cell lines: MV4-11 and RS4;11 cells Concentrations: Dissolved in DMSO, final concentration ~20 μM Incubation Time: 72 hours Method: Cells are cultured overnight in low serum media (0.5% FBS), seeded in a 96-well plate at 40 000 cells per well and exposed to AC220 for 72 hours at 37 °C. Cell viability is measured using the Cell Titer-Blue Cell Viability Assa (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female NU/NU or severe combined immunodeficient mice implanted with MV4-11 cells Dosages: ~10 mg/kg Administration: Oral gavage (Only for Reference)

References

[1] Zarrinkar PP, et al. Blood, 2009, 114(14), 2984-2992.

Solubility (25°C)

In vitro	DMSO	33 mg/mL (58.85 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 15% Captisol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Quizartinib (AC220) SDF

Molecular Weight	560.67
Formula	C₂₉H₃₂N₆O₄S
CAS No.	950769-58-1
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04459585	Active not recruiting	Drug: Dabigatran Etexilate Mesylate\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 17 2020	Early Phase 1
NCT04459598	Active not recruiting	Drug: Efavirenz\|Drug: Quizartinib	Healthy Subjects\|Drug-drug Interaction\|Pharmacokinetics\|Quizartinib	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 8 2020	Early Phase 1
NCT04473664	Recruiting	Drug: Quizartinib	Hepatic Impairment\|Moderate Impaired Hepatic Function	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	September 29 2020	Phase 1
NCT04209725	Recruiting	Drug: CPX-351\|Drug: Quizartinib	Leukemia Myeloid Acute	SCRI Development Innovations LLC	June 3 2020	Phase 2
NCT02984995	Completed	Drug: Quizartinib	Leukemia Myeloid Acute	Daiichi Sankyo Co. Ltd.\|Daiichi Sankyo Inc.	December 8 2016	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it possible to alter the captisol concentration to make it more dissolvable i.e 20% or 25% captisol ?
Answer:
In 15% Captisol, the compound forms s suspension at 30mg/ml. Increasing the percentage of Captisol will not convert the mixture into solution. You can use suspension for oral gavage feeding.

Target Protein Ligand Inhibitors with Unique Features

FLT3 Inhibitor in Clinical Trial

Dovitinib (TKI-258, CHIR-258) : Phase III for Metastatic Renal Cell Carcinoma.
Newest FLT3 Inhibitor

TCS 359 : Potent FLT3 inhibitor with IC50 of 42 nM.

Choose Your Country or Region

By Signaling Pathways

By product type

Quizartinib (AC220)